Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Annals of Neurology|October 10, 2025
Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis OnsetSteve Simpson-Yap, Ellen Morwitch, Samuel A Tanner, et al.BMJ Neurology Open|December 26, 2025
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trialKayla Ward, Vivien Li, Sudarshini Ramanathan, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 11, 2024
Employment, work hours, and wages in adults with myelin oligodendrocyte glycoprotein antibody disease: An international cohort studyAndrew Siyoon Ham, Isabella Gomez Hjerthen, Akshatha Sudhir, et al.Pageof 7